SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis. (Q51814272)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

title

SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author

Jean-Jacques Kiladjian

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Ronan Chaligné

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

William Vainchenker

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

C Tonetti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

R Besancenot

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

C Marty

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

G Socié

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

D Bordessoule

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

S Giraudier

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

French Intergroup for MPD

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

19 February 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

1186-1190

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19225535%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2009.22

21 January 2020

exact match

0 references

cites work

Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.22

7 January 2021

Regulation of cytokine signaling by SOCS family molecules

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.22

7 January 2021

Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.22

7 January 2021

Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.22

7 January 2021

Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.22

7 January 2021

Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.22

7 January 2021

Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.22

7 January 2021

Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.22

7 January 2021

P19INK4D links endomitotic arrest and megakaryocyte maturation and is regulated by AML-1.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.22

7 January 2021

Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.22

7 January 2021

The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.22

7 January 2021

5-Azacitidine has limited therapeutic activity in myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.22

7 January 2021